533
Views
0
CrossRef citations to date
0
Altmetric
Special Focus Issue: Expert Review of Vaccines 10-year anniversary - Foreword

Expert Review of Vaccines 10-year anniversary issue

&
Pages 1489-1491 | Published online: 09 Jan 2014

References

  • Goldberg R. Is there a future for vaccines? Expert Rev. Vaccines1(1), 1–3 (2002).
  • Koganty RR. Vaccines: exploiting the role of Toll-like receptors. Expert Rev. Vaccines1(2), 123–124 (2002).
  • von Herrath MG. Vaccination to prevent Type 1 diabetes. Expert Rev. Vaccines1(1), 25–28 (2002).
  • Bethell D, Pollard AJ. Meningococcal vaccines. Expert Rev. Vaccines1(1), 75–84 (2002).
  • Godlee F. Conflicts of interest and pandemic flu. BMJ340, c2947 (2010).
  • Boisgérault F, Morón G, Leclerc C. Virus-like particles: a new family of delivery systems. Expert Rev. Vaccines1(1), 101–109 (2002).
  • zur Hausen H. HPV vaccines: what remains to be done? Expert Rev. Vaccines10(11), 1505–1507 (2011).
  • Chris Elias. The Decade of Vaccines Collaboration: developing a global roadmap for saving lives. Expert Rev. Vaccines10(11), 1493–1495 (2011).
  • Poolman JT, Hallander H, Halperin SA. Pertussis vaccines: where to now? Expert Rev. Vaccines10(11), 1497–1500 (2011).
  • Ben-Yedidia T, Rudolph W. A universal influenza vaccine: the BiondVax story. Expert Rev. Vaccines10(11), 1509–1512 (2011).
  • Cao W, Jin Kim JH, Chirkova T et al. Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Rev. Vaccines10(11), 1529–1537 (2011).
  • Zhang J, Tarbet EB, Toro H, Tang DC. Adenovirus-vectored drug–vaccine duo as a potential driver for conferring mass protection against infectious diseases. Expert Rev. Vaccines10(11), 1539–1552 (2011).
  • Murshid A, Gong J, Stevenson MA, Calderwood SK. Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev. Vaccines10(11), 1553–1568 (2011).
  • Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev. Vaccines10(11), 1569–1583 (2011).
  • Igietseme JU, Eko FO, Black CM. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev. Vaccines10(11), 1585–1596 (2011).
  • Wu X, Smith TG, Rupprecht CE. From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev. Vaccines10(11), 1597–1608 (2011).
  • Chen LH, Hill DR, Wilder-Smith A. Vaccination of travelers: how far have we come and where are we going? Expert Rev. Vaccines10(11), 1609–1620 (2011).
  • Borrow R, Dagan R, Zepp F, Hallander H, Poolman J. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev. Vaccines10(11), 1621–1631 (2011).
  • Vajo Z. The seasonal influenza vaccine Agriflu®. Expert Rev. Vaccines10(11), 1513–1517 (2011).
  • Puig-Barberà J, Pérez-Vilar S, Díez-Domingo J. MF59™-adjuvanted seasonal influenza vaccine in young children. Expert Rev. Vaccines10(11), 1519–1528 (2011).
  • Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature473, 463–469 (2011).
  • Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol.10(1), 116–125 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.